Novartis, Blackstone Life Sciences to launch heart drug company

Private equity firm Blackstone Life Sciences has partnered with Swiss drugmaker Novartis to launch a company to develop a heart drug, according to The Wall Street Journal.

The new company, Anthos Therapeutics, will start by advancing a Novartis antibody that targets two clotting factors. The idea is to develop a drug that treats blood clots in acute and chronic situations to prevent a variety of cardiovascular disorders.

The company is backed by a $250 million investment from Blackstone, which will control the company. Novartis will have a minority stake.

Read the full report here.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars